Last reviewed · How we verify
EOC237
At a glance
| Generic name | EOC237 |
|---|---|
| Sponsor | Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EOC237 CI brief — competitive landscape report
- EOC237 updates RSS · CI watch RSS
- Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd portfolio CI